T2 Biosystems (TTOO) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

TTOO Stock Forecast

T2 Biosystems stock forecast is as follows: an average price target of $5.00 (represents a 880.39% upside from TTOO’s last price of $0.51) and a rating consensus of 'Hold', based on 1 wall street analysts offering a 1-year stock forecast.

TTOO Price Target

The average price target for T2 Biosystems (TTOO) is $5.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $5.00 to $5.00. This represents a potential 880.39% upside from TTOO's last price of $0.51.

TTOO Analyst Ratings

Hold

According to 1 Wall Street analysts, T2 Biosystems's rating consensus is 'Hold'. The analyst rating breakdown for TTOO stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 1 'Hold' (100.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

T2 Biosystems Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Jul 30, 2024	Kyle Mikson	Canaccord Genuity	$5.00	$4.74	5.49%	880.39%

Row per page

Go to

The latest T2 Biosystems stock forecast, released on Jul 30, 2024 by Kyle Mikson from Canaccord Genuity, set a price target of $5.00, which represents a 5.49% increase from the stock price at the time of the forecast ($4.74), and a 880.39% increase from TTOO last price ($0.51).

T2 Biosystems Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	1
Avg Price Target	-	-	$5.00
Last Closing Price	$0.51	$0.51	$0.51
Upside/Downside	-100.00%	-100.00%	880.39%

In the current month, the average price target of T2 Biosystems stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to T2 Biosystems's last price of $0.51. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Jul 30, 2024	Canaccord Genuity	Hold	Hold	Hold

Row per page

Go to

T2 Biosystems's last stock rating was published by Canaccord Genuity on Jul 30, 2024. The company gave TTOO a "Hold" rating, the same as its previous rate.

T2 Biosystems Financial Forecast

T2 Biosystems Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
Revenue	-	-	-	-	-	-	-	-	-	-	$1.96M	$2.08M	$5.48M	$3.68M	$5.91M	$7.23M	$6.98M	$7.43M	$6.69M	$6.96M	$7.79M	$5.25M	$2.55M	$2.54M	$3.07M	$1.68M	$1.80M	$1.78M	$2.31M	$941.00K
Avg Forecast	$7.28M	$6.16M	$5.24M	$4.44M	$3.69M	$2.85M	$2.10M	$1.60M	$2.40M	$1.50M	$2.17M	$2.33M	$5.39M	$4.72M	$6.14M	$6.65M	$6.19M	$5.79M	$6.14M	$6.43M	$7.96M	$5.14M	$2.36M	$2.63M	$3.39M	$2.04M	$2.00M	$1.41M	$2.38M	$901.79K
High Forecast	$7.28M	$6.16M	$5.24M	$4.44M	$3.69M	$2.85M	$2.10M	$1.63M	$2.61M	$1.50M	$2.17M	$2.33M	$5.39M	$4.72M	$6.14M	$6.65M	$6.19M	$5.79M	$6.14M	$6.43M	$7.96M	$5.14M	$2.36M	$2.63M	$3.39M	$2.04M	$2.00M	$1.41M	$2.85M	$1.08M
Low Forecast	$7.28M	$6.16M	$5.24M	$4.44M	$3.69M	$2.85M	$2.10M	$1.57M	$2.19M	$1.50M	$2.17M	$2.33M	$5.39M	$4.72M	$6.14M	$6.65M	$6.19M	$5.79M	$6.14M	$6.43M	$7.96M	$5.14M	$2.36M	$2.63M	$3.39M	$2.04M	$2.00M	$1.41M	$1.90M	$721.43K
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	9	9	9	9	13	13	13	13	15	8
Surprise %	-	-	-	-	-	-	-	-	-	-	0.91%	0.89%	1.02%	0.78%	0.96%	1.09%	1.13%	1.28%	1.09%	1.08%	0.98%	1.02%	1.08%	0.97%	0.91%	0.82%	0.90%	1.27%	0.97%	1.04%

T2 Biosystems's average Quarter revenue forecast for Sep 23 based on 1 analysts is $1.50M, with a low forecast of $1.50M, and a high forecast of $1.50M. TTOO's average Quarter revenue forecast represents a -23.63% decrease compared to the company's last Quarter revenue of $1.96M (Jun 23).

T2 Biosystems EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	9	9	9	9	13	13	13	13	15	8
EBITDA	-	-	-	-	-	-	-	-	-	-	$-13.05M	$-14.11M	$-9.74M	$-15.23M	$-14.47M	$-14.27M	$-9.63M	$-11.46M	$-10.19M	$-8.84M	$-9.07M	$-9.04M	$-8.83M	$-12.63M	$-11.47M	$-11.40M	$-12.68M	$-12.47M	$-10.72M	$-12.37M
Avg Forecast	$-7.28M	$-6.16M	$-5.24M	$-4.44M	$-3.69M	$-2.85M	$-2.10M	$-7.22M	$-2.40M	$-1.50M	$-2.17M	$-7.72M	$-9.28M	$-4.72M	$-6.14M	$-8.26M	$-6.19M	$-5.79M	$-6.14M	$-8.84M	$-7.96M	$-5.14M	$-2.36M	$-13.18M	$-3.39M	$-2.04M	$-2.00M	$-10.80M	$-11.01M	$-11.83M
High Forecast	$-7.28M	$-6.16M	$-5.24M	$-4.44M	$-3.69M	$-2.85M	$-2.10M	$-5.78M	$-2.19M	$-1.50M	$-2.17M	$-6.18M	$-7.43M	$-4.72M	$-6.14M	$-6.61M	$-6.19M	$-5.79M	$-6.14M	$-7.07M	$-7.96M	$-5.14M	$-2.36M	$-10.55M	$-3.39M	$-2.04M	$-2.00M	$-8.64M	$-8.80M	$-9.47M
Low Forecast	$-7.28M	$-6.16M	$-5.24M	$-4.44M	$-3.69M	$-2.85M	$-2.10M	$-8.67M	$-2.61M	$-1.50M	$-2.17M	$-9.27M	$-11.14M	$-4.72M	$-6.14M	$-9.91M	$-6.19M	$-5.79M	$-6.14M	$-10.60M	$-7.96M	$-5.14M	$-2.36M	$-15.82M	$-3.39M	$-2.04M	$-2.00M	$-12.96M	$-13.21M	$-14.20M
Surprise %	-	-	-	-	-	-	-	-	-	-	6.01%	1.83%	1.05%	3.22%	2.36%	1.73%	1.56%	1.98%	1.66%	1.00%	1.14%	1.76%	3.74%	0.96%	3.38%	5.60%	6.35%	1.15%	0.97%	1.05%

undefined analysts predict TTOO's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than T2 Biosystems's previous annual EBITDA (undefined) of $NaN.

T2 Biosystems Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	9	9	9	9	13	13	13	13	15	8
Net Income	-	-	-	-	-	-	-	-	-	-	$-6.35M	$-20.04M	$-11.45M	$-18.95M	$-21.05M	$-18.13M	$-14.10M	$-13.96M	$-12.47M	$-10.66M	$-9.91M	$-11.26M	$-10.69M	$-14.95M	$-14.04M	$-14.17M	$-15.65M	$-15.15M	$-12.91M	$-14.70M
Avg Forecast	$-4.12M	$-5.01M	$-5.90M	$-7.16M	$-8.77M	$-11.45M	$-17.36M	$-8.71M	$-39.72M	$-415.65M	$-477.14M	$-9.32M	$-11.37M	$-2.98B	$-6.34B	$-9.97M	$-6.36B	$-6.11B	$-5.45B	$-10.66M	$-4.78B	$-5.50B	$-10.57B	$-15.60M	$-19.15B	$-22.08B	$-22.73B	$-13.13M	$-13.26M	$-14.06M
High Forecast	$-4.12M	$-5.01M	$-5.90M	$-7.16M	$-8.77M	$-11.45M	$-17.36M	$-6.97M	$-39.72M	$-415.65M	$-477.14M	$-7.46M	$-9.09M	$-2.98B	$-6.34B	$-7.97M	$-6.36B	$-6.11B	$-5.45B	$-8.53M	$-4.78B	$-5.50B	$-10.57B	$-12.48M	$-19.15B	$-22.08B	$-22.73B	$-10.50M	$-10.61M	$-11.25M
Low Forecast	$-4.12M	$-5.01M	$-5.90M	$-7.16M	$-8.77M	$-11.45M	$-17.36M	$-10.46M	$-39.72M	$-415.65M	$-477.14M	$-11.18M	$-13.64M	$-2.98B	$-6.34B	$-11.96M	$-6.36B	$-6.11B	$-5.45B	$-12.79M	$-4.78B	$-5.50B	$-10.57B	$-18.72M	$-19.15B	$-22.08B	$-22.73B	$-15.75M	$-15.91M	$-16.88M
Surprise %	-	-	-	-	-	-	-	-	-	-	0.01%	2.15%	1.01%	0.01%	0.00%	1.82%	0.00%	0.00%	0.00%	1.00%	0.00%	0.00%	0.00%	0.96%	0.00%	0.00%	0.00%	1.15%	0.97%	1.05%

T2 Biosystems's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. TTOO's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

T2 Biosystems SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	9	9	9	9	13	13	13	13	15	8
SG&A	-	-	-	-	-	-	-	-	-	-	$6.30M	$7.30M	$6.67M	$7.02M	$7.82M	$9.23M	$6.54M	$8.54M	$7.24M	$6.20M	$4.60M	$5.08M	$5.11M	$6.50M	$7.55M	$5.98M	$6.72M	$7.05M	$5.75M	$5.87M
Avg Forecast	$15.00M	$12.70M	$10.79M	$9.14M	$7.60M	$5.87M	$4.32M	$3.30M	$4.94M	$3.09M	$4.47M	$4.80M	$11.11M	$9.73M	$12.64M	$5.80M	$12.74M	$11.91M	$12.65M	$6.20M	$16.39M	$10.59M	$4.86M	$5.43M	$6.98M	$4.19M	$4.11M	$2.90M	$4.89M	$1.86M
High Forecast	$15.00M	$12.70M	$10.79M	$9.14M	$7.60M	$5.87M	$4.32M	$3.35M	$5.37M	$3.09M	$4.47M	$4.80M	$11.11M	$9.73M	$12.64M	$6.96M	$12.74M	$11.91M	$12.65M	$7.44M	$16.39M	$10.59M	$4.86M	$5.43M	$6.98M	$4.19M	$4.11M	$2.90M	$5.87M	$2.23M
Low Forecast	$15.00M	$12.70M	$10.79M	$9.14M	$7.60M	$5.87M	$4.32M	$3.24M	$4.51M	$3.09M	$4.47M	$4.80M	$11.11M	$9.73M	$12.64M	$4.64M	$12.74M	$11.91M	$12.65M	$4.96M	$16.39M	$10.59M	$4.86M	$5.43M	$6.98M	$4.19M	$4.11M	$2.90M	$3.91M	$1.49M
Surprise %	-	-	-	-	-	-	-	-	-	-	1.41%	1.52%	0.60%	0.72%	0.62%	1.59%	0.51%	0.72%	0.57%	1.00%	0.28%	0.48%	1.05%	1.20%	1.08%	1.43%	1.63%	2.43%	1.18%	3.16%

T2 Biosystems's average Quarter SG&A projection for Sep 23 is $3.09M, based on 1 Wall Street analysts, with a range of $3.09M to $3.09M. The forecast indicates a -50.94% fall compared to TTOO last annual SG&A of $6.30M (Jun 23).

T2 Biosystems EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	9	9	9	9	13	13	13	13	15	8
EPS	-	-	-	-	-	-	-	-	-	-	$-7.84	$-1.47	$-2.25K	$-3.15	$-5.95	$-5.34	$-4.24	$-4.21	$-4.03	$-3.60	$-3.34	$-3.81	$-4.44	$-10.89	$-10.23	$-15.60	$-17.61	$-17.10	$-17.95	$-24.08
Avg Forecast	$-0.23	$-0.28	$-0.33	$-0.40	$-0.49	$-0.64	$-0.97	$-1.86	$-2.22	$-23.23	$-26.67	$-120.22	$-233.00	$-211.32	$-450.00	$-372.88	$-450.88	$-433.33	$-386.54	$-370.00	$-338.90	$-390.00	$-750.00	$-1.18K	$-1.36K	$-1.57K	$-1.61K	$-1.51K	$-0.38	$-0.44
High Forecast	$-0.23	$-0.28	$-0.33	$-0.40	$-0.49	$-0.64	$-0.97	$-1.86	$-2.22	$-23.23	$-26.67	$-120.22	$-233.00	$-211.32	$-450.00	$-372.88	$-450.88	$-433.33	$-386.54	$-370.00	$-338.90	$-390.00	$-750.00	$-1.18K	$-1.36K	$-1.57K	$-1.61K	$-1.51K	$-0.30	$-0.35
Low Forecast	$-0.23	$-0.28	$-0.33	$-0.40	$-0.49	$-0.64	$-0.97	$-1.86	$-2.22	$-23.23	$-26.67	$-120.22	$-233.00	$-211.32	$-450.00	$-372.88	$-450.88	$-433.33	$-386.54	$-370.00	$-338.90	$-390.00	$-750.00	$-1.18K	$-1.36K	$-1.57K	$-1.61K	$-1.51K	$-0.46	$-0.53
Surprise %	-	-	-	-	-	-	-	-	-	-	0.29%	0.01%	9.64%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	47.23%	54.72%

According to undefined Wall Street analysts, T2 Biosystems's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to TTOO previous annual EPS of $NaN (undefined).

T2 Biosystems Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
TTOO	T2 Biosystems	$0.51	$5.00	880.39%	Hold
ILMN	Illumina	$130.74	$202.44	54.84%	Buy
DHR	Danaher	$230.06	$305.47	32.78%	Buy
TMO	Thermo Fisher Scientific	$501.29	$642.48	28.17%	Buy
IDXX	IDEXX Laboratories	$419.83	$479.75	14.27%	Buy
WAT	Waters	$355.47	$356.80	0.37%	Buy
HTGM	HTG Molecular Diagnostics	$0.48	$0.17	-64.58%	Buy

TTOO Forecast FAQ

Is T2 Biosystems a good buy?

No, according to 1 Wall Street analysts, T2 Biosystems (TTOO) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 0 'Buy' recommendations, accounting for 0% of TTOO's total ratings.

What is TTOO's price target?

T2 Biosystems (TTOO) average price target is $5 with a range of $5 to $5, implying a 880.39% from its last price of $0.51. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will T2 Biosystems stock go up soon?

According to Wall Street analysts' prediction for TTOO stock, the company can go up by 880.39% (from the last price of $0.51 to the average price target of $5), up by 880.39% based on the highest stock price target, and up by 880.39% based on the lowest stock price target.

Can T2 Biosystems stock reach $1?

TTOO's average twelve months analyst stock price target of $5 supports the claim that T2 Biosystems can reach $1 in the near future.

What are T2 Biosystems's analysts' financial forecasts?

T2 Biosystems's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $10.24M (high $10.26M, low $10.21M), average EBITDA is $-15.861M (high $-14.417M, low $-17.306M), average net income is $-46.288M (high $-44.545M, low $-48.031M), average SG&A $21.09M (high $21.14M, low $21.03M), and average EPS is $-3.96 (high $-3.96, low $-3.96). TTOO's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $23.13M (high $23.13M, low $23.13M), average EBITDA is $-23.125M (high $-23.125M, low $-23.125M), average net income is $-22.187M (high $-22.187M, low $-22.187M), average SG&A $47.62M (high $47.62M, low $47.62M), and average EPS is $-1.24 (high $-1.24, low $-1.24).

Did the TTOO's actual financial results beat the analysts' financial forecasts?

Based on T2 Biosystems's last annual report (Dec 2022), the company's revenue was $22.3M, which missed the average analysts forecast of $22.91M by -2.62%. Apple's EBITDA was $-55.471M, beating the average prediction of $-28.404M by 95.29%. The company's net income was $-63.37M, missing the average estimation of $-9.343B by -99.32%. Apple's SG&A was $30.74M, missing the average forecast of $39.27M by -21.71%. Lastly, the company's EPS was $-12.42, missing the average prediction of $-1.267K by -99.02%. In terms of the last quarterly report (Jun 2023), T2 Biosystems's revenue was $1.96M, missing the average analysts' forecast of $2.17M by -9.49%. The company's EBITDA was $-13.051M, beating the average prediction of $-2.17M by 501.43%. T2 Biosystems's net income was $-6.347M, missing the average estimation of $-477M by -98.67%. The company's SG&A was $6.3M, beating the average forecast of $4.47M by 40.89%. Lastly, the company's EPS was $-7.84, missing the average prediction of $-26.667 by -70.60%